List of centrally authorised products with safety-related changes to the product information

List of centrally authorised products with safety-related changes to the product information

Source updated: Aug 31, 2026

Primary source: EMA - What's new RSS

PV Impact Brief

Urgency: HighConfidence: high

What changed

A new list has been published detailing centrally authorised products that have undergone safety-related changes to their product information.

Why it matters

These changes have direct regulatory implications for labeling and could affect how products are communicated to healthcare professionals and patients.

Action needed

Review and update labeling processes in accordance with the newly published safety-related changes for affected products.

Relevant for: Labeling LeadRegulatory Intelligence Lead
Processes impacted: Labeling
Owner: Regulatory Intelligence Lead
Review cadence: Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Aug 31, 2026

EMA - What's new RSS →Updated August 31, 2026

Full briefing

Practical implication

Review and update labeling processes in accordance with the newly published safety-related changes for affected products.

The document details products with safety-related changes that impact labeling requirements.

What changed: A new list has been published detailing centrally authorised products that have undergone safety-related changes to their product information.

Why it matters: These changes have direct regulatory implications for labeling and could affect how products are communicated to healthcare professionals and patients.

Practical implication: Review and update labeling processes in accordance with the newly published safety-related changes for affected products.

View original source

Source: EMA - What's new RSS
Published at source: 2026-08-31T00:00:00.000Z
Discovered by monitor: 2026-08-31T21:31:31.240Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Labeling #Safety Signals #Source-ingestion #Regulator-monitor #European Union #Ema.europa.eu

Related updates for your role

publicEuropean Medicines Agency (EMA) · European Union · Updated Aug 31, 2026

Guidance for industry on implementing Shortage Prevention Plans (SPP)

MAHs must allocate resources to develop and maintain SPPs, ensuring they meet the new regulatory requirements and are ready for submission within two days upon request in crisis situations.

Country ComplianceRegulatory Intelligence Lead

SOP Impact1 SOPs

Relevant for: Regulatory Intelligence Lead

verifiedRegulatory action: Latest

Read impact briefarrow_forward

publicFDA · USA · Updated Aug 31, 2026

FDA Approves Treatment for Essential Thrombocythemia

Implementation of new dosing schedules and an emphasis on monitoring for potential adverse reactions as outlined in the prescribing information.

LabelingRegulatory Intelligence Lead

SOP Impact1 SOPs

Relevant for: Regulatory Intelligence Lead, Labeling Lead

verifiedRegulatory action: Latest

Read impact briefarrow_forward

publicFDA · USA · Updated Aug 31, 2026

International Collaboration to Advance New Testing Methods That Reduce Reliance on Horseshoe Crab Blood

Regulatory compliance processes may need updates to incorporate the new recombinant endotoxins testing method and guidelines established under the ICMRA framework.

Inspection ReadinessCountry ComplianceRegulatory Intelligence Lead

SOP Impact2 SOPs

Relevant for: Regulatory Intelligence Lead, PV Quality Lead

verifiedRegulatory action: Regulators

Read impact briefarrow_forward

publicANSM (France) · France · Updated Aug 31, 2026Translated From French

Withdrawal of FastPen 40mg Product by AZRL LTD

AZRL LTD must proceed with the recall of FastPen 40mg from all locations and suspend marketing activities until compliance is verified.

Signal ManagementRegulatory Intelligence Lead

SOP Impact1 SOPs

Relevant for: Regulatory Intelligence Lead, Medical Safety Lead

verifiedRegulatory action: Regulators

Read impact briefarrow_forward